| Androgen receptor activity in T cells limits checkpoint blockade efficacy X Guan, F Polesso, C Wang, A Sehrawat, RM Hawkins, SE Murray, ... Nature 606 (7915), 791-796, 2022 | 258 | 2022 |
| Tgfβ signaling is critical for maintenance of the tendon cell fate GK Tan, BA Pryce, A Stabio, JV Brigande, CJ Wang, Z Xia, SF Tufa, ... Elife 9, e52695, 2020 | 81 | 2020 |
| Nudt21 regulates the alternative polyadenylation of Pak1 and is predictive in the prognosis of glioblastoma patients Y Chu, N Elrod, C Wang, L Li, T Chen, A Routh, Z Xia, W Li, EJ Wagner, ... Oncogene 38 (21), 4154-4168, 2019 | 72 | 2019 |
| A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth RL Plews, A Mohd Yusof, C Wang, M Saji, X Zhang, CS Chen, MD Ringel, ... The Journal of Clinical Endocrinology & Metabolism 100 (5), E748-E756, 2015 | 69 | 2015 |
| RCAN1-4 is a thyroid cancer growth and metastasis suppressor C Wang, M Saji, SE Justiniano, AM Yusof, X Zhang, L Yu, S Fernández, ... JCI insight 2 (5), 2017 | 56 | 2017 |
| Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro YW Koh, MH Shah, K Agarwal, SK McCarty, BS Koo, VJ Brendel, C Wang, ... Endocrine-related cancer 19 (1), 29-38, 2012 | 45 | 2012 |
| Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration Y Ma, SK McCarty, NP Kapuriya, VJ Brendel, C Wang, X Zhang, ... The Journal of Clinical Endocrinology & Metabolism 98 (8), E1314-E1322, 2013 | 35 | 2013 |
| Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model M Saji, CS Kim, C Wang, X Zhang, T Khanal, K Coombes, K La Perle, ... Scientific reports 10 (1), 18316, 2020 | 10 | 2020 |
| Localization of CaSR antagonists in CaSR-expressing medullary thyroid cancer H Ding, AM Yusof, S Kothandaraman, M Saji, C Wang, K Kumar, K Milum, ... The Journal of Clinical Endocrinology & Metabolism 98 (11), E1722-E1729, 2013 | 5 | 2013 |
| BREAKING INSIGHTS X Guan, F Polesso, C Wang, A Sehrawat, RM Hawkins, SE Murray Cancer Res 82, 9, 2022 | | 2022 |
| Abstract PR10: Heterogenous activation of multiple suppressive pathways by scRNAseq may underscore resistance to PD-1 therapy in metastatic castration-resistant prostate cancer C Wang, J Graff, Z Xia, A Moran Cancer Immunology Research 8 (4 Supplement), PR10-PR10, 2020 | | 2020 |
| METASTASIS SUPPRESSOR RCAN1-4 ENHANCES BRAFV600E-INDUCED THYROID TUMORIGENESIS IN ASSOCIATION WITH NRF3 ACTIVATION AND IMMUNE INFILTRATION J Tan, X Shen, R Liu, G Zhu, L Rooper, M Xing, X ZHU, B West, S Cheng, ... Thyroid 28 (S1), A-169-A-198, 2018 | | 2018 |
| Characterizing the Role of RCAN1-4 in Thyroid Cancer Growth and Metastasis C Wang The Ohio State University, 2017 | | 2017 |
| RCAN1-4 is a Novel Metastasis Suppressor Gene C Wang, A Mohd-Yusof, H Nakanishi, M Saji, MD Ringel Endocrine Reviews 36 (2 Supplement), i1–i1599, 2015 | | 2015 |
